Brandli, Alice
Khong, Fay L.
Kong, Roy C. K.
Kelly, Darren J.
Fletcher, Erica L.
Funding for this research was provided by:
National Health and Medical Research Council (1141587)
Article History
Received: 1 October 2021
Accepted: 15 December 2021
First Online: 17 January 2022
Competing interests
: Prof. D.K. is employed by OccuRx Pty Ltd, shareholder of Occurx Pty Ltd and has issued patents relating to the composition of OCX063 and its use for eye diseases. Prof. E.F. received funding support by Occurx Pty Ltd to conduct the research reported here. Dr. A.B. institution received payment by Occurx Pty Ltd to conduct research reported here otherwise is funded by NHMRC ID:1141587. Dr FK is a current employee of Occurx Pty Ltd. Dr. RK received payment as a consultant to Occurx Pty Ltd.